| Combination Chemotherapy with Cisplatin , Etoposide , and Ifosfamide ( PIE ) in the Advanced Non - Small Cell Lung Cancer |
| Sang Won Shin, Byung Soo Kim, Jae Jung Shin, Yeul Hong Kim, Kyung Ho Kang, Young Ho Choi, Kwang Tak Kim, Jun Suk Kim |
1Department of Internal Medicine, College of Medicine, Korea University, Seoul Korea.
2Department of Chest Surgery, College of Medicine, Korea University, Seoul Korea.
|
|
|
|
|
|
| ABSTRACT |
PURPOSE:
Combination chemotherapy with cisplatin and etoposide have been considered as one of the chemotherpy regimen for non small cell lung cacer(NSCLC) with the response rate of 20~40%. Ifosfamide is one of the most active agent against NSCLC. And so, we initiated a phase II trial for advanced NSCLC to determine the effect of PIE(cisplatin, ifosfamide, etoposide) regimen.
MATERIALS AND METHODS:
36 patients with inoperable non-small cell lung cancer who had no prior systemic chemotherapy were treated with combined ifosfamide (1,800 mg/m2 plus mesna 1,100 mg/m2 by intravenous continuous infusion daily for 3 days) with cisplatin (20 mg/m2 intravenous for 3 days) and etoposide (80 mg/m2 intravenous for 3 days). We evaluated the response rate, survival and toxicities of these patients.
RESULTS:
The objective response rate was 28%(CR; 2/36, 6%, PR; 8/36, 22%). Among 10 responders, 7 patients were in good ECOG performance status(0~1). The mean survival of all these patients were 43 weeks(8~141 weeks); the responding patients survived longer than the non-responders(median survival; 59 weeks vs 28 weeks, p<0.05). The toxicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION:
We concluded that PIE regimen is effective in the treatment of advanced non-small cell lung cancer with acceptable toxicities and long-term follow up is warranted. |
| Key words:
Ifosfamide;Cisplatin;Etoposide;Non-small cell lung cancer;Chemotherapy |
|
PDF Links
Full text via DOI 
Download Citation 
